Histological Differentiation Provides Useful, Additive and Independent Prognostic Information to Proliferation Index in G2 and G3 Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)

被引：0

作者：

Sanchez Canovas, M. ^{[1
]}

Nunez, B. ^{[2
,3
]}

Benavent, M. ^{[4
]}

Teule, A. ^{[5
]}

Segura, A. ^{[6
]}

Beguiristain, A. ^{[7
]}

Martinez del Prado, M. P. ^{[8
]}

Castellano, D. ^{[2
]}

Sevilla, I ^{[9
]}

Villabona, C. ^{[10
]}

Matos, I ^{[11
]}

Crespo, G. ^{[12
]}

Escudero, P. ^{[13
]}

Garcia Centeno, R. ^{[14
]}

Garcia-Carbonero, R. ^{[2
]}

机构：

[1] Hosp Univ Morales Meseguer, Med Oncol Dept, Murcia, Spain

[2] Hosp Univ Doce Octubre, Med Oncol Dept, Madrid, Spain

[3] Fdn BBVA Carolina, Madrid, Spain

[4] Hosp Univ Virgen del Rocio, Med Oncol Dept, Seville, Spain

[5] Hosp Duran & Reynalds, Inst Catalan Oncol, Med Oncol Dept, Barcelona, Spain

[6] Hosp Univ La Fe, Med Oncol Dept, Valencia, Spain

[7] Hosp Univ Donostia, Surg Dept, San Sebastian, Spain

[8] Hosp Univ Basurto, Med Oncol Dept, Bilbao, Spain

[9] Hosp Clin & Reg Malaga, Med Oncol Dept, Malaga, Spain

[10] Hosp Univ Bellvitge, Endocrinol Dept, Barcelona, Spain

[11] Hosp Univ Vall dHebron, Med Oncol Dept, Barcelona, Spain

[12] Complejo Asistencial Univ Burgos, Med Oncol Dept, Burgos, Spain

[13] Hosp Clin Univ Lozano Blesa, Med Oncol Dept, Zaragoza, Spain

[14] Hosp Univ Gregorio Maranon, Endocrinol Dept, Madrid, Spain

来源：

NEUROENDOCRINOLOGY | 2017年 / 105卷

关键词：

who; 2010; classification;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

G15

引用

页码：137 / 137

页数：1

共 12 条

[1] Classification of Lung Neuroendocrine Neoplasms (Lung-NENs) According to WHO 2010 for Gastroenteropancreatic NENs (GEP-NENs) Has Prognostic Relevance and Includes Lung-NETs G3
Kasajima, A.
Oka, N.
Ishida, H.
Sakurada, A.
Kameya, T.
Konukiewitz, B.
Kloeppel, G.
Weichert, W.
Ishikawa, Y.
Okada, Y.
Sasano, H.
[J]. NEUROENDOCRINOLOGY, 2017, 105 : 133 - 133
[2] Characteristics, Treatments and Inflammatory Biomarkers in Patients (pts) with G3 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)
Cameselle-Garcia, S.
Sardo, E.
Landolfi, S.
Merino-Casabiel, X.
Sanchez, J. L.
Balsells, J.
Pando, E.
Blanco, L.
Diez, M.
Acosta, D.
Capdevila, J.
Hernando, J.
[J]. NEUROENDOCRINOLOGY, 2020, 110 : 64 - 64
[3] T-cell Infiltrate in GEP-NENs: identification and Evaluation of Its Distribution among the WHO G1, G2 and G3 NENs
Milione, Massimo
Pellegrinelli, Alessio
Centonze, Giovanni
Dominoni, Francesca
Coppa, Joregelina
Pusceddu, Sara
Buzzoni, Roberto
Giacomelli, Luca
Mazzaferro, Vincenzo
De Braud, Filippo
Anichini, Andrea
[J]. LABORATORY INVESTIGATION, 2016, 96 : 151A - 151A
[4] T-cell Infiltrate in GEP-NENs: identification and Evaluation of Its Distribution among the WHO G1, G2 and G3 NENs
Milione, Massimo
Pellegrinelli, Alessio
Centonze, Giovanni
Dominoni, Francesca
Coppa, Joregelina
Pusceddu, Sara
Buzzoni, Roberto
Giacomelli, Luca
Mazzaferro, Vincenzo
De Brand, Filippo
Anichini, Andrea
[J]. MODERN PATHOLOGY, 2016, 29 : 151A - 151A
[5] Prognostic and predictive factors of platinum-based chemotherapy in gastroenteropancreatic neuroendocrine neoplasms G3
Kolasinska-Cwikla, A.
Cwikla, J.
Roszkowska-Purska, K.
Samsel, R.
Cichocki, A.
Palucki, J.
Wyrwicz, L.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S164 - S164
[6] NICENEC phase 2 trial of nivolumab and platinum-doublet chemotherapy in untreated advanced G3 Neuroendocrine Neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin: Efficacy by differentiation, KI67 index and primary tumor site
Riesco-Martinez, M. D. C.
Capdevila, J.
Alonso, V
Jimenez-Fonseca, P.
Teule, A.
Grande, E.
Sevilla, I
Vinuales M, Benavent
Alonso-Gordoa, T.
Custodio, A.
Hernando, J.
Garcia-Carbonero, R.
[J]. JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 190 - 190
[7] Is proliferative index (Ki-67) useful to stratify patients (pts) with G2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)? Clinicopathologic correlation.
Angel, Martin
Connor, Juan O.
Pesce, Veronica
Ariel Mendez, Guillermo
Bestani, Claudia
Marmissolle, Fabiana
Giacomi, Nora
Belli, Susana
Domenichini, Enzo
Chacon, Matias
Zamora, Victor
Maria Cabanne, Ana
Parma, Patricia
Luis Roca, Enrique
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[8] Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin
Riesco Martinez, M. C.
Capdevila Castillon, J.
Alonso, V.
Jimenez-Fonseca, P.
Teule, A.
Grande, E.
Sevilla, I.
Benavent, M.
Alonso-Gordoa, T.
Custodio, A.
Anton Pascual, B.
Hernando, J.
Polo, E.
Castillo Trujillo, O. A.
Garcia-Carbonero, R.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S769 - S769
[9] Is proliferative index (Ki 67) useful to stratify patients (pts) with G2 gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs)? Clinicopathologic correlation.
Connor, Juan O.
Angel, Martin
Pesce, Veronica
Ariel Mendez, Guillermo
Bestani, Claudia
Marmissolle, Fabiana
Giacomi, Nora
Belli, Susana
Domenichini, Enzo
Chacon, Matias
Zamora, Victor
Maria Cabanne, Ana
Parma, Patricia
Luis Roca, Enrique
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[10] Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)
Riesco-Martinez, M. C.
Capdevila, J.
Alonso, V.
Jimenez-Fonseca, P.
Teule, A.
Grande, E.
Sevilla, I.
Benavent Vinuales, M.
Alonso-Gordoa, T.
Custodio, A.
Hernando, J.
Polo, E.
Castillo Trujillo, O. A.
Garcia-Carbonero, R.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S908 - S909

← 1 2 →